Skip to main content
Top
Published in: Journal of General Internal Medicine 9/2012

01-09-2012 | Original Research

Association Between Race, Depression, and Antiretroviral Therapy Adherence in a Low-Income Population with HIV Infection

Authors: Meg C. Kong, PhD, Milap C. Nahata, MS, PharmD, Veronique A. Lacombe, PhD, Eric E. Seiber, PhD, Rajesh Balkrishnan, PhD

Published in: Journal of General Internal Medicine | Issue 9/2012

Login to get access

Abstract

Background

Racial disparities exist in many aspects of HIV/AIDS. Comorbid depression adds to the complexity of disease management. However, prior research does not clearly show an association between race and antiretroviral therapy (ART) adherence, or depression and adherence. It is also not known whether the co-existence of depression modifies any racial differences that may exist.

Objective

To examine racial differences in ART adherence and whether the presence of comorbid depression moderates these differences among Medicaid-enrolled HIV-infected patients.

Design

Retrospective cohort study.

Setting

Multi-state Medicaid database (Thomson Reuters MarketScan®).

Participants

Data for 7,034 HIV-infected patients with at least two months of antiretroviral drug claims between 2003 and 2007 were assessed.

Main Measures

Antiretroviral therapy adherence (90 % days covered) were measured for a 12-month period. The main independent variables of interest were race and depression. Other covariates included patient variables, clinical variables (comorbidity and disease severity), and therapy-related variables.

Key Results

In this study sample, over 66 % of patients were of black race, and almost 50 % experienced depression during the study period. A significantly higher portion of non-black patients were able to achieve optimal adherence (≥90 %) compared to black patients (38.6 % vs. 28.7 %, p < 0.001). In fact, black patients had nearly 30 % decreased odds of being optimally adherent to antiretroviral drugs compared to non-black patients (OR = 0.70, 95 % CI: 0.63–0.78), and was unchanged regard less of whether the patient had depression. Antidepressant treatment nearly doubled the odds of optimal ART adherence among patients with depression (OR = 1.92, 95 % CI: 1.12–3.29).

Conclusions

Black race was significantly associated with worse ART adherence, which was not modified by the presence of depression. Under-diagnosis and under-treatment of depression may hinder ART adherence among HIV-infected patients of all races.
Literature
1.
go back to reference Kraut-Becher J, Eisenberg M, Voytek C, Brown T, Metzger DS, Aral S. Examining racial disparities in HIV. J Acquir Immune Defic Syndr. 2008;47(Suppl 1):S20–S27.PubMed Kraut-Becher J, Eisenberg M, Voytek C, Brown T, Metzger DS, Aral S. Examining racial disparities in HIV. J Acquir Immune Defic Syndr. 2008;47(Suppl 1):S20–S27.PubMed
2.
go back to reference Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520–529.PubMedCrossRef Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520–529.PubMedCrossRef
3.
go back to reference Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States. JAMA. 1999;281:2305–2315.PubMedCrossRef Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States. JAMA. 1999;281:2305–2315.PubMedCrossRef
4.
go back to reference Cunningham WE, Anderson RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care. 1999;37:1270–1281.PubMedCrossRef Cunningham WE, Anderson RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care. 1999;37:1270–1281.PubMedCrossRef
5.
go back to reference Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38:96.PubMedCrossRef Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38:96.PubMedCrossRef
6.
go back to reference Palacio H, Kahn JG, Richards TA, et al. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Reports (Washington, DC: 1974), June 2002. 117(3):233–251; discussion 231–232. Palacio H, Kahn JG, Richards TA, et al. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Reports (Washington, DC: 1974), June 2002. 117(3):233–251; discussion 231–232.
9.
go back to reference Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2001;26:82–92.PubMedCrossRef Kleeberger CA, Phair JP, Strathdee SA, Detels R, Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2001;26:82–92.PubMedCrossRef
10.
go back to reference Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the multicenter AIDS cohort study. AIDS. 2004;18:683–688.PubMedCrossRef Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the multicenter AIDS cohort study. AIDS. 2004;18:683–688.PubMedCrossRef
11.
go back to reference Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. JIDS. 2005;38:320–328. Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. JIDS. 2005;38:320–328.
12.
go back to reference Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among white, Hispanic, and black men in the MACS cohort. J Acquir Immune Defic Syndr. 2009;52:290–293.PubMedCrossRef Oh DL, Sarafian F, Silvestre A, et al. Evaluation of adherence and factors affecting adherence to combination antiretroviral therapy among white, Hispanic, and black men in the MACS cohort. J Acquir Immune Defic Syndr. 2009;52:290–293.PubMedCrossRef
13.
go back to reference Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386–395.PubMedCrossRef Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386–395.PubMedCrossRef
14.
go back to reference Golin C, Liu H, Hays R, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756–765.PubMedCrossRef Golin C, Liu H, Hays R, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756–765.PubMedCrossRef
15.
go back to reference Thrasher AD, Earp JAL, Golin CE, et al. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49:84–93.PubMedCrossRef Thrasher AD, Earp JAL, Golin CE, et al. Discrimination, distrust, and racial/ethnic disparities in antiretroviral therapy adherence among a national sample of HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49:84–93.PubMedCrossRef
16.
go back to reference Schackman BR, Ribaudo HJ, Krambrink A, et al. Racial differences in virologic failure associated with adherence and quality of life on Efavirenz-Containing regimens for initial HIV therapy. J Acquir Immune Defic Syndr. 2007;46:547–554.PubMedCrossRef Schackman BR, Ribaudo HJ, Krambrink A, et al. Racial differences in virologic failure associated with adherence and quality of life on Efavirenz-Containing regimens for initial HIV therapy. J Acquir Immune Defic Syndr. 2007;46:547–554.PubMedCrossRef
17.
go back to reference Weiser SD, Riley ED, Ragland K, Hammer G, Clark R, Bangsberg DR. Brief report: factors associated with depression among homeless and marginally housed HIV Infected men in San Francisco. J Gen Intern Med. 2006;21:61–64.PubMedCrossRef Weiser SD, Riley ED, Ragland K, Hammer G, Clark R, Bangsberg DR. Brief report: factors associated with depression among homeless and marginally housed HIV Infected men in San Francisco. J Gen Intern Med. 2006;21:61–64.PubMedCrossRef
18.
go back to reference Asch S, Kilbourne A, Gifford A, et al. Underdiagnosis of depression in HIV. J Gen Intern Med. 2003;18:450–460.PubMedCrossRef Asch S, Kilbourne A, Gifford A, et al. Underdiagnosis of depression in HIV. J Gen Intern Med. 2003;18:450–460.PubMedCrossRef
19.
go back to reference Yun LW, Maravi M, Kobayashi JS, et al. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38:432–438.PubMedCrossRef Yun LW, Maravi M, Kobayashi JS, et al. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38:432–438.PubMedCrossRef
20.
go back to reference Grenard JL, Munjas BA, Adams JL, et al. Depression and medication adherence in the treatment of chronic diseases in the United States: a Meta-analysis. J Gen Intern Med. 2011;26:1175–1182.PubMedCrossRef Grenard JL, Munjas BA, Adams JL, et al. Depression and medication adherence in the treatment of chronic diseases in the United States: a Meta-analysis. J Gen Intern Med. 2011;26:1175–1182.PubMedCrossRef
21.
go back to reference DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–2107.PubMedCrossRef DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–2107.PubMedCrossRef
22.
go back to reference Shacham E, Nurutdinova D, Satyanarayana V, et al. Routine screening for depression: identifying a challenge for successful HIV care. AIDS Patient Care STDS. 2009;23:949–955.PubMedCrossRef Shacham E, Nurutdinova D, Satyanarayana V, et al. Routine screening for depression: identifying a challenge for successful HIV care. AIDS Patient Care STDS. 2009;23:949–955.PubMedCrossRef
23.
go back to reference Cook JA, Cohen MH, Burke J, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr. 2002;30:401–409.PubMed Cook JA, Cohen MH, Burke J, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr. 2002;30:401–409.PubMed
24.
go back to reference Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA. 2001;285:1466–1474.PubMedCrossRef Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV epidemiology research study. JAMA. 2001;285:1466–1474.PubMedCrossRef
25.
go back to reference Burack JH, Barrett DC, Stall RD, et al. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993;270:2568–2573.PubMedCrossRef Burack JH, Barrett DC, Stall RD, et al. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993;270:2568–2573.PubMedCrossRef
26.
go back to reference Leserman J, Petitto JM, Perkins DO, et al. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. a 2-year follow-up study. Arch Gen Psychiatry. 1997;54:279–285.PubMedCrossRef Leserman J, Petitto JM, Perkins DO, et al. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. a 2-year follow-up study. Arch Gen Psychiatry. 1997;54:279–285.PubMedCrossRef
27.
go back to reference Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:384–90.PubMedCrossRef Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:384–90.PubMedCrossRef
28.
go back to reference Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45:394–402.PubMedCrossRef Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics. 2004;45:394–402.PubMedCrossRef
29.
go back to reference Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763–1769.PubMedCrossRef Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763–1769.PubMedCrossRef
30.
go back to reference Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20:418–428.PubMedCrossRef Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20:418–428.PubMedCrossRef
31.
go back to reference Robinson MJ, Qaqish RB. Practical psychopharmacology in HIV-1 and acquired immunodeficiency syndrome. Psychiatr Clin North Am. 2002;25:149–175.PubMedCrossRef Robinson MJ, Qaqish RB. Practical psychopharmacology in HIV-1 and acquired immunodeficiency syndrome. Psychiatr Clin North Am. 2002;25:149–175.PubMedCrossRef
32.
go back to reference Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry. 1999;156:101–107.PubMed Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry. 1999;156:101–107.PubMed
33.
go back to reference Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Jul 8, 2008. pp. 1–98. Available at http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed February 20, 2012. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Jul 8, 2008. pp. 1–98. Available at http://​aidsinfo.​nih.​gov/​ContentFiles/​PerinatalGL.​pdf. Accessed February 20, 2012.
35.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.PubMedCrossRef Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.PubMedCrossRef
36.
go back to reference Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38:911–925.PubMedCrossRef Turner BJ, Newschaffer CJ, Zhang D, et al. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38:911–925.PubMedCrossRef
37.
go back to reference Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000;95:167–73.PubMedCrossRef Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol. 2000;95:167–73.PubMedCrossRef
38.
go back to reference Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed
39.
go back to reference Martin M, Del CE, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24:1263–1268.PubMedCrossRef Martin M, Del CE, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008;24:1263–1268.PubMedCrossRef
40.
go back to reference Kyser M, Buchacz K, Bush TJ, et al. Factors associated with non-adherence to antiretroviral therapy in the SUN study. AIDS Care. 2011;23(5):601–611.PubMedCrossRef Kyser M, Buchacz K, Bush TJ, et al. Factors associated with non-adherence to antiretroviral therapy in the SUN study. AIDS Care. 2011;23(5):601–611.PubMedCrossRef
41.
go back to reference Lima VD, Harrigan R, Murry M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371–2380.PubMedCrossRef Lima VD, Harrigan R, Murry M, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371–2380.PubMedCrossRef
42.
go back to reference Boulware LE, Cooper LA, Ratner LE, et al. Race and trust in the health care system. Public Health Rep. 2003;118:358–65.PubMed Boulware LE, Cooper LA, Ratner LE, et al. Race and trust in the health care system. Public Health Rep. 2003;118:358–65.PubMed
43.
go back to reference Das AK, Olfson M, McCurtis HL, et al. Depression in African Americans: breaking barriers to detection and treatment. J Fam Pract. 2006;55:30–39.PubMed Das AK, Olfson M, McCurtis HL, et al. Depression in African Americans: breaking barriers to detection and treatment. J Fam Pract. 2006;55:30–39.PubMed
44.
go back to reference Melfi CA, Croghan TW, Hanna MP, et al. Racial variation in antidepressant treatment in a Medicaid population. J Clin Psychiatry. 2000;16:16–21.CrossRef Melfi CA, Croghan TW, Hanna MP, et al. Racial variation in antidepressant treatment in a Medicaid population. J Clin Psychiatry. 2000;16:16–21.CrossRef
45.
go back to reference Dunlop DD, Song J, Lyons JS, Mannheim LM, Chang RW. Racial/ethnic differences in rates of depression among pre-retirement adults. Am J Public Health. 2003;93:1945–1952.PubMedCrossRef Dunlop DD, Song J, Lyons JS, Mannheim LM, Chang RW. Racial/ethnic differences in rates of depression among pre-retirement adults. Am J Public Health. 2003;93:1945–1952.PubMedCrossRef
46.
go back to reference Kessler RC, Berglund P, Demler O, et al. National comorbidity survey replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.PubMedCrossRef Kessler RC, Berglund P, Demler O, et al. National comorbidity survey replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.PubMedCrossRef
47.
go back to reference Walkup JT, Boyer CA, Kellermann SL. Reliability of Medicaid claims files for use in psychiatric diagnoses and service delivery. Adm Policy Ment Health. 2000;27:129–139.PubMedCrossRef Walkup JT, Boyer CA, Kellermann SL. Reliability of Medicaid claims files for use in psychiatric diagnoses and service delivery. Adm Policy Ment Health. 2000;27:129–139.PubMedCrossRef
48.
go back to reference Gilmer T, Kronick R, Fishman P, et al. The Medicaid Rx model: pharmacy-based risk adjustment for public programs. Med Care. 2001;39:1188–1202.PubMedCrossRef Gilmer T, Kronick R, Fishman P, et al. The Medicaid Rx model: pharmacy-based risk adjustment for public programs. Med Care. 2001;39:1188–1202.PubMedCrossRef
Metadata
Title
Association Between Race, Depression, and Antiretroviral Therapy Adherence in a Low-Income Population with HIV Infection
Authors
Meg C. Kong, PhD
Milap C. Nahata, MS, PharmD
Veronique A. Lacombe, PhD
Eric E. Seiber, PhD
Rajesh Balkrishnan, PhD
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 9/2012
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-012-2043-3

Other articles of this Issue 9/2012

Journal of General Internal Medicine 9/2012 Go to the issue

Healing Arts: Materia Medica

“Cancer Kills 1, Self; Wounds 3”

Healing Arts: Materia Medica

No Loneliness on His Face

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.